Verizon: the top five benefits of 5G technology in healthcare
As the adoption of 5G continues around the world, we take a look at Verizon’s top five ways in which 5G can benefit healthcare.
By harnessing augmented and virtual reality (AR/VR) applications, alongside the use of 5G technology in medical training, students could be transported from multiple locations, into one operating room with near real time views of delicate procedures.
Remote physical therapy
To combat lack of proximity to healthcare professionals providing rehabilitative care, AR/VR applications and 5G technology could be used to make interactions between patients and their physical therapists much smoother and more frequent.
Hologram aided diagnostics and surgical intervention
Despite the huge innovative leap the healthcare industry has made, professionals still rely on 2D information to understand the 3D anatomy of a person. Harnessing 5G for its speed, bandwidth and low latency could transform MRI scans into high quality holographic images that could be referenced - in near real time - to project on to a patient or use mixed reality lenses, to minimise guesswork.
Remote patient monitoring
With the near real time connectivity and low latency of 5G, health trackers could gather and transmit complex, clinical-grade data, providing the potential to diagnose and treat patients more quickly - potentially reducing medical costs.
Accelerating ER readiness
By harnessing 5G from the offset with first responders, the technology could have the potential to improve outcomes when milliseconds matter. With the use of 5G, data could reach hospitals in near real time to allow faster deployment of life-saving resources at the hospital. This technology could also help first responders provide more accurate assessments for doctors.
For more information on healthcare topics - please take a look at the latest edition of Healthcare Global.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.